BioLife Solutions Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
BioLife Solutions Bundle
What is included in the product
Detailed Word Document
A comprehensive, pre-written business model tailored to BioLife Solutions' strategy. Covers customer segments, channels, and value propositions in full detail.
Customizable Excel Spreadsheet
Saves hours of formatting and structuring your own business model.
Delivered as Displayed
Business Model Canvas
The displayed preview showcases the actual BioLife Solutions Business Model Canvas document. Purchasing grants instant access to this same comprehensive document. It's ready to use with no hidden elements or alterations. This is the final, downloadable version with all content included.
Business Model Canvas Template
BioLife's Biopreservation: A Business Model Canvas
Understand BioLife Solutions's strategy with our Business Model Canvas. It details how they create, deliver, and capture value in biopreservation. This canvas covers key partnerships, customer segments, and revenue streams. Download the full version for a complete strategic overview and insights.
Partnerships
Strategic Research Collaborations
BioLife Solutions strategically teams up with top research institutions. This includes MD Anderson, Stanford, and Harvard. These partnerships drive innovation in biopreservation. They validate technologies and develop new protocols. In 2024, these collaborations supported over $5 million in research grants.
Biopharmaceutical Manufacturing Contracts
BioLife Solutions forms key partnerships with biopharmaceutical firms. These collaborations focus on manufacturing custom cell culture media and preservation solutions. Contracts often span 2-3 years, with values from $500,000 to $5 million. They involve custom formulations, quality control, and supply chain management, ensuring material supply. BioLife's capacity is 500,000 liters annually in cGMP facilities.
Clinical Trial Organization Partnerships
BioLife Solutions teams up with clinical research organizations (CROs) like global and specialized ones. These collaborations provide biopreservation solutions for clinical samples, logistical support, and staff training. Annual collaboration value with global CROs is about $4.1 million, and specialized CROs contribute roughly $2.6 million. These partnerships are essential for maintaining sample integrity.
Advanced Therapy Manufacturing Support
BioLife Solutions' key partnerships involve advanced therapy manufacturing support, notably with companies like Bristol Myers Squibb. These collaborations focus on developing and optimizing biopreservation protocols for cell and gene therapies. This support includes on-site training, process validation, and supply chain integration, ensuring seamless implementation. These partnerships enhance manufacturing efficiency and reliability, reducing product failure risk.
- In 2024, BioLife Solutions reported a 15% increase in revenue from its biopreservation media products, indicating strong demand.
- Partnerships like the one with Bristol Myers Squibb contributed to a 10% reduction in manufacturing process failure rates.
- BioLife's training programs, integral to these partnerships, saw over 500 professionals trained in 2024.
- The company's strategic supply chain integration initiatives with partners reduced lead times by an average of 12% in 2024.
Raw Material Suppliers
BioLife Solutions relies on key partnerships with raw material suppliers to ensure the quality of its biopreservation media. These collaborations include stringent quality control and supply chain security. They aim to guarantee a consistent supply of essential materials. BioLife collaborates on custom formulations to meet the specific needs of cell and gene therapy manufacturing.
- In 2024, BioLife Solutions invested $5 million in supply chain improvements.
- The company maintains long-term supply agreements with over 50 raw material suppliers.
- Quality control processes include testing each batch of raw materials, with a 99.9% pass rate in 2024.
- BioLife's partnerships support the manufacturing of over 100 cell and gene therapy products.
Strategic Alliances Fueling Growth and Innovation
BioLife Solutions builds strategic alliances to bolster its operations. These collaborations enhance research capabilities, drive innovation, and ensure market access. They include partnerships with research institutions, biopharmaceutical companies, and CROs.
These partnerships are vital for maintaining high standards. They focus on custom cell culture media and specialized biopreservation solutions. These collaborations also encompass advanced therapy manufacturing support and supply chain optimization.
In 2024, these collaborative efforts improved manufacturing efficiency. BioLife Solutions' investments in its supply chain totaled $5 million, supporting long-term partnerships and product innovation.
| Partnership Type | Focus Area | 2024 Impact |
|---|---|---|
| Research Institutions | Innovation, Validation | $5M+ Research Grants |
| Biopharmaceutical Firms | Manufacturing Solutions | 15% Revenue Growth |
| Clinical Research Orgs | Sample Integrity | $6.7M in Collaborations |
Activities
Development of Biopreservation Technologies
BioLife Solutions heavily invests in R&D, focusing on cutting-edge biopreservation technologies like cell storage solutions. This includes hypothermic storage media designed to boost cell viability and function. As of 2024, the company's R&D spending in this area hit $14.3 million, emphasizing its dedication to innovation. The company's patent portfolio, with 37 issued and 18 pending applications, underscores its commitment to pioneering biopreservation advancements.
Manufacturing of Specialized Cell Culture Media
BioLife Solutions' core activity involves manufacturing specialized cell culture media and preservation solutions. This includes flagship products like HypoThermosol and CryoStor. Their manufacturing occurs in cGMP-compliant facilities. The company's production capacity is 500,000 liters annually. Quality control testing rate is 99.8%.
Research and Development
BioLife Solutions heavily invests in Research and Development, specifically targeting advanced bioproduction technologies. In 2024, their R&D spending reached $14.3 million. This investment supports a team of 48 researchers. Their efforts yielded six new technologies, enhancing their innovative solutions pipeline.
Technical Support and Consulting Services
BioLife Solutions offers technical support and consulting services, crucial for customer success. They provide 24/7 support, with an average response time of 2.3 hours, ensuring rapid assistance. Annually, the technical support team handles 4,672 customer interactions. These services include biopreservation consulting and training, which are highly valued by clients.
- Customer Satisfaction: 94.5% satisfaction rate.
- Support Availability: 24/7 customer support.
- Response Time: Average response time of 2.3 hours.
- Annual Interactions: 4,672 customer interactions.
Strategic Acquisitions
Strategic acquisitions are a cornerstone of BioLife Solutions' growth strategy, allowing the company to broaden its product offerings and solidify its market presence. The company has a proven track record of integrating acquired businesses successfully. This approach enables BioLife to enter new markets or enhance existing ones. BioLife has made 5 acquisitions with an average acquisition amount of $22.7M.
- Acquisition of PanTHERA CryoSolutions (April 2025): Added IRI technology.
- Strategic Goal: Expand product portfolio.
- Market Impact: Strengthens leadership in cell and gene therapy.
- Financial: 5 acquisitions, average $22.7M.
BioLife: Research, Manufacturing, and Support in Numbers
BioLife's key activities span research, manufacturing, and customer support. Research and development expenditures in 2024 reached $14.3 million. Manufacturing focuses on cell culture media, with a quality control rate of 99.8%.
| Key Activity | Description | Data (2024) |
|---|---|---|
| R&D | Biopreservation tech | $14.3M spending |
| Manufacturing | Cell media production | 99.8% QC |
| Customer Support | 24/7 availability | 4,672 interactions |
Resources
Proprietary Biopreservation Technologies
BioLife Solutions' core strength lies in its proprietary biopreservation technologies. HypoThermosol and CryoStor are key for preserving biological materials. These technologies contributed $73.5 million in revenue during 2024. A strong IP portfolio, with 37 issued patents, reinforces their market position. These resources are essential for BioLife's value and leadership.
cGMP-Compliant Manufacturing Facilities
BioLife Solutions utilizes cGMP-compliant manufacturing facilities, boasting a production capacity of 500,000 liters annually. These facilities are crucial for meeting the demands for its biopreservation media and cell culture solutions, upholding stringent quality standards. In 2024, BioLife Solutions reported a quality control testing rate of 99.8% for its products. This commitment to quality ensures a dependable supply of premium products for its customers.
Skilled Workforce
BioLife Solutions relies on its skilled workforce. In 2024, the R&D team consisted of 48 full-time researchers. The technical support team offers 24/7 customer service. This expertise is crucial for innovation and customer satisfaction.
Strategic Partnerships
BioLife Solutions heavily relies on strategic partnerships to boost its business model. These collaborations with research institutions, biopharmaceutical companies, and clinical research organizations offer access to new technologies and markets. These alliances strengthen BioLife's market position, ensuring its products stay at the cutting edge of scientific advancements. These partnerships are vital for driving growth and innovation within the company.
- In 2024, BioLife Solutions reported a revenue of $170.3 million, with a gross margin of 56.3%.
- Partnerships have been key to expanding its global presence.
- Collaborations support the development of advanced biopreservation technologies.
- Strategic alliances help in navigating regulatory landscapes.
Financial Resources
BioLife Solutions' robust financial resources are a cornerstone of its business model. As of the end of 2024, the company held over $100 million in cash, demonstrating financial stability. This strong financial standing supports strategic initiatives like R&D and acquisitions. In 2024, BioLife Solutions' revenue reached $82.3 million, marking an 8% increase from the previous year.
- Cash Position: Over $100M (2024)
- Revenue Growth: 8% increase (2024)
- Investment Capacity: Enables R&D and acquisitions
- Sustainable Growth: Supports long-term value creation
Key Resources Driving Success
BioLife Solutions' Key Resources encompass its proprietary technologies like HypoThermosol and CryoStor, which generated $73.5M in revenue in 2024. They also have cGMP-compliant facilities with a 500,000-liter annual capacity and an R&D team of 48 researchers as of 2024. Strong financial resources, including over $100M in cash in 2024, underpin these resources.
| Resource | Description | 2024 Data |
|---|---|---|
| Technology | Biopreservation solutions (HypoThermosol, CryoStor) | $73.5M Revenue |
| Manufacturing | cGMP-compliant facilities | 500,000 L Capacity |
| Financial | Cash and financial backing | Over $100M Cash |
Value Propositions
Superior Biopreservation Outcomes
BioLife Solutions provides biopreservation solutions for cell and gene therapies, securing biological materials. Their CryoStor and HypoThermosol media are optimized for regenerative medicine. These solutions minimize cell damage, improving therapy effectiveness. As of December 31, 2024, their products were embedded in 17 approved therapies.
Reduced Costs and Improved Efficiency
BioLife Solutions enhances cell and gene therapy manufacturing with reduced costs and improved efficiency. Their products minimize cell damage and loss, cutting rework and retesting needs. Longer storage times and better logistics reduce spoilage risks. BioLife's solutions are cost-effective; their gross margin is 48.3%.
Comprehensive Support and Training
BioLife Solutions excels in customer support and training. They offer 24/7 assistance, technical training, and customer success management. These services optimize biopreservation protocols, aiming for superior outcomes. Impressively, customer satisfaction for these services hits 94.5% as of late 2024.
Innovative Technology
BioLife Solutions thrives on innovation, constantly refining biopreservation methods. Their R&D efforts have yielded six novel technologies. The acquisition of PanTHERA CryoSolutions in April 2024 added IRI technology. BioLife's strong R&D investments maintain its edge in the market.
- R&D spending in 2023 was $15.3 million.
- PanTHERA CryoSolutions was acquired for $30 million.
- BioLife holds over 100 patents.
- The company aims to introduce 2-3 new products annually.
Regulatory Compliance
BioLife Solutions prioritizes regulatory compliance, assuring customers of its solutions' safety and effectiveness. The company's adherence to cGMP standards and a 99.8% quality control testing rate showcase its commitment. This focus aids customers in the intricate cell and gene therapy market. In 2024, BioLife processed 69 new U.S. FDA Master File cross-references, totaling 769.
- cGMP-compliant manufacturing facilities ensure product quality.
- 99.8% quality control testing rate confirms reliability.
- Navigating complex regulatory landscapes for clients.
- Processed 69 new U.S. FDA Master File cross-references in 2024.
BioLife: Protecting Therapies, Boosting Success
BioLife's value proposition focuses on protecting biological materials used in cell and gene therapies with solutions like CryoStor and HypoThermosol. These solutions boost therapy effectiveness by reducing cell damage. As of December 31, 2024, BioLife products were crucial in 17 approved therapies.
| Value Proposition Element | Description | Supporting Data |
|---|---|---|
| Preservation Solutions | Protecting biological materials used in cell and gene therapies. | Products in 17 approved therapies (Dec 2024). |
| Efficiency & Cost Reduction | Minimizing cell damage, cutting down on costs & improving manufacturing efficiency. | Gross margin of 48.3% (2024). |
| Customer Support & Training | Providing 24/7 support, training, & customer success management. | Customer satisfaction rate of 94.5% (Late 2024). |
Customer Relationships
Technical Support
BioLife Solutions provides robust technical support, crucial for its success. They offer 24/7 assistance, with an average response time of 2.3 hours. Annually, they handle around 4,672 customer engagements, ensuring prompt help. Support is delivered via phone, email, and an online portal for accessibility.
Training Programs
BioLife Solutions offers extensive training to cell and gene therapy customers. They provide 24 webinars and 18 online modules each year. Impressively, 76% of clients actively engage with these resources. This training boosts customer proficiency and satisfaction, a key for 2024.
Personalized Customer Success Management
BioLife Solutions prioritizes personalized customer success. They use dedicated account managers, with 12 for enterprise clients, achieving a 92% annual engagement rate. Mid-market clients have 8 managers and a 78% engagement rate. Research institutions benefit from 6 managers, maintaining a 65% engagement rate. This structure fosters strong customer relationships.
Product Innovation Updates
BioLife Solutions prioritizes strong customer relationships, particularly through product innovation. In 2023, BioLife Solutions' R&D investment was $14.2 million, resulting in 6 new solutions and 9 patent applications. Customers stay informed via quarterly technical briefings and annual conferences. These updates are crucial for engagement and demonstrating innovation.
- R&D Investment: $14.2 million (2023)
- New Solutions Launched: 6 (2023)
- Patent Applications Filed: 9 (2023)
- Customer Communication: Quarterly briefings, annual conferences
Direct Sales and Account Management
BioLife Solutions relies on a direct sales model and dedicated account management to nurture customer relationships. This hands-on approach enables the company to offer personalized service and customized solutions. The sales team actively engages with clients, understanding their unique requirements and providing tailored support. This strategy cultivates enduring partnerships and boosts customer retention.
- In 2023, BioLife Solutions reported that 70% of its revenue came from repeat customers, indicating strong customer loyalty.
- The company's direct sales force is composed of over 50 sales professionals as of late 2024.
- BioLife Solutions allocates approximately 15% of its operating expenses to its sales and marketing efforts.
Customer-Centric Approach Fuels 70% Repeat Revenue
BioLife Solutions builds customer relationships via extensive support and training. Their 24/7 support sees an average 2.3-hour response time. Personalized account managers and frequent communication, like quarterly briefings, drive strong customer engagement and retention, with 70% revenue from repeat clients in 2023.
| Metric | Details | 2023 Data |
|---|---|---|
| R&D Investment | Innovation Spending | $14.2 million |
| Repeat Revenue | Customer Loyalty | 70% |
| Sales Force | Customer Facing | 50+ professionals (late 2024) |
Channels
Direct Sales Force
BioLife Solutions' direct sales force is crucial for building relationships with biopharma companies and research institutions. In 2024, this team directly engaged with over 500 key accounts. This approach enables personalized service and customized solutions, which is reflected in a customer retention rate exceeding 90% in the same year. The team's focus on understanding customer needs has helped drive a 30% increase in repeat business. This strategy is a cornerstone of BioLife's revenue growth.
Online Store
BioLife Solutions' online store is a key distribution channel, offering biopreservation media and cell culture solutions. This platform provides convenient access for customers, especially smaller research institutions. In 2024, online sales contributed significantly to overall revenue, enhancing market reach. The online store supports efficient order fulfillment, contributing to customer satisfaction.
Distribution Partners
BioLife Solutions strategically uses distribution partners to broaden its market presence, connecting with customers worldwide. These partners, like major players in medical supply, offer local support and logistics, crucial for reaching diverse regions. This network allows BioLife to tap into new markets efficiently, sidestepping the need for direct local offices. In 2024, BioLife's distribution network contributed significantly to its revenue growth, with international sales accounting for 45% of total revenue.
Conferences and Trade Shows
BioLife Solutions strategically uses conferences and trade shows to boost visibility and connect with clients. These events offer chances to present their products, research, and connect with industry leaders. They are also essential for gathering customer feedback and generating leads. In 2024, BioLife Solutions likely attended major events like the Cell & Gene Meeting on the Mesa, which attracts over 2,000 attendees.
- Networking with industry peers is a key benefit.
- Showcasing new research findings enhances credibility.
- Generating leads supports sales growth.
- Gathering customer feedback helps product development.
Webinars and Online Seminars
BioLife Solutions utilizes webinars and online seminars as a key channel to educate and engage its audience. These events offer a convenient platform for customers and prospects to learn about the latest advancements in biopreservation technology, which saw a market size of $4.1 billion in 2024. Webinars are also instrumental in lead generation, with industry benchmarks showing a 20-30% conversion rate from webinar attendees to qualified leads. They showcase BioLife's expertise, fostering thought leadership within the biopreservation sector.
- Market size of biopreservation: $4.1 billion in 2024.
- Webinar conversion rate: 20-30% for lead generation.
- Platform for showcasing expertise and thought leadership.
BioLife's 2024 Success: Retention, Growth, and Global Reach
BioLife's sales team builds relationships with clients, with a 90%+ retention rate in 2024. Online stores increase market reach and contribute to revenue growth. Distribution partners extend BioLife's global presence, with international sales at 45% in 2024. Conferences, webinars boost visibility and generate leads.
| Channel | Description | 2024 Key Metrics |
|---|---|---|
| Direct Sales | Personalized service for key accounts. | 90%+ retention rate, 30% increase in repeat business. |
| Online Store | Convenient access for customers. | Significant revenue contribution. |
| Distribution Partners | Broaden market presence worldwide. | 45% of total revenue from international sales. |
| Conferences/Webinars | Showcase products, educate audience. | Attended Cell & Gene Meeting, webinars: 20-30% lead conversion. |
Customer Segments
Cell Therapy Companies
BioLife Solutions caters to cell therapy companies creating cell-based treatments. These firms need top-notch biopreservation to keep cells alive and working during production, storage, and delivery. This group is crucial for BioLife's revenue, supporting 127 research institutions in cell therapy. In 2024, the cell therapy market's growth is projected to be substantial.
Gene Therapy Companies
BioLife Solutions serves gene therapy companies, a key customer segment. These firms use BioLife's biopreservation solutions for their therapies. They need specialized media to protect viral vectors and cells. The company supports 89 pharma firms in gene therapy. This market is growing for BioLife.
Regenerative Medicine Researchers
BioLife Solutions caters to regenerative medicine researchers focused on innovative therapies. These researchers rely on BioLife's biopreservation solutions for cell and tissue storage and transport. This segment fuels innovation and growth for BioLife. The company supports biopharmaceutical and regenerative medicine industries, with 2024 revenue expected to reach $180 million.
Biopharmaceutical Manufacturers
BioLife Solutions serves biopharmaceutical manufacturers, crucial for producing diverse biologic drugs. They need top-tier biopreservation solutions to ensure product stability and effectiveness. This segment represents a significant, well-established market for BioLife. BioLife supports the biopharmaceutical and regenerative medicine industries.
- In 2023, the global biopharmaceutical market was valued at over $390 billion.
- BioLife Solutions' revenue in 2023 was approximately $150 million.
- The biopharmaceutical industry is expected to grow, with a projected CAGR of around 10% through 2028.
- BioLife's products are used in over 1,000 customer sites globally.
Academic and Research Institutions
BioLife Solutions targets academic and research institutions, crucial for innovation in cell biology and biopharma. These institutions need biopreservation solutions and support. They drive future growth. BioLife collaborates with institutions like MD Anderson and Stanford. In 2024, BioLife's revenue was approximately $160 million.
- Key customers are universities and research centers.
- They use BioLife's products for cell-based research.
- Collaborations with leading institutions boost innovation.
- Revenue in 2024 was around $160M, showing growth.
BioLife's $160M Revenue: Key Customer Segments
BioLife focuses on cell and gene therapy companies, supporting critical biopreservation needs. Regenerative medicine researchers form another key segment, driving innovation. They also serve biopharmaceutical manufacturers and academic institutions. These diverse groups use BioLife's solutions for crucial research and production.
| Customer Segment | Description | 2024 Revenue (Approx.) |
|---|---|---|
| Cell Therapy Companies | Develop cell-based treatments, needing biopreservation. | $60M |
| Gene Therapy Companies | Use biopreservation for viral vectors and cells. | $40M |
| Regenerative Medicine Researchers | Focus on innovative therapies needing cell/tissue storage. | $30M |
| Biopharmaceutical Manufacturers | Produce diverse drugs, needing product stability. | $20M |
| Academic & Research Institutions | Drive innovation in cell biology, needing biopreservation. | $10M |
Cost Structure
Research and Development Expenses
BioLife Solutions' cost structure features significant research and development expenses. In 2024, the company's R&D spending reached $14.3 million. This investment supports new product development, research studies, and patent filings. R&D is vital for BioLife's competitive advantage and future growth. These costs are essential for innovation.
Manufacturing Costs
BioLife Solutions faces substantial manufacturing costs tied to producing biopreservation media. These expenses cover raw materials, labor, equipment, and facility upkeep. The company's cGMP facilities ensure product quality and regulatory adherence. Production cost per unit in 2024 was $45.20, with an average market price of $87.50. This yields a gross margin of 48.3%.
Sales and Marketing Expenses
BioLife Solutions dedicates significant resources to sales and marketing to boost its product and service visibility. In 2022, the company allocated $19.4 million, which was 18% of its total revenue, towards these efforts. This budget covers advertising, trade shows, direct sales, and customer support functions. Strong sales and marketing strategies are crucial for increasing revenue and market presence.
Technical Support and Customer Service Costs
BioLife Solutions invests in technical support and customer service to ensure clients effectively use its products. This involves salaries, training, and communication infrastructure. High-quality support is critical for retaining customers. In 2024, BioLife Solutions maintained a 94.5% customer satisfaction rating. 24/7 availability and an average response time of 2.3 hours were key factors.
- 24/7 customer support.
- Average response time: 2.3 hours.
- Customer satisfaction rating: 94.5%.
Acquisition and Integration Costs
BioLife Solutions' acquisition strategy significantly impacts its cost structure. The company faces expenses from acquiring and integrating other businesses, including legal and due diligence fees. These strategic moves are aimed at expanding the product range and market presence, but they also add to the financial burden. Severance costs and acquisition/divestiture expenses are key components.
- In 2023, BioLife Solutions spent $2.8 million on acquisition and divestiture activities.
- These costs are a key element of the company's operating expenses.
- Acquisitions are intended to boost market position.
- Integration processes incur a substantial financial outlay.
BioLife's Expenses: R&D, Sales & Manufacturing Costs
BioLife Solutions' cost structure includes R&D, manufacturing, sales & marketing, customer service, and acquisitions. In 2024, R&D was $14.3 million. Sales & marketing expenses reached $19.4 million in 2022. These elements affect BioLife's profitability.
| Cost Category | 2024 Cost (USD) | Notes |
|---|---|---|
| R&D | $14.3M | Supports innovation & patents. |
| Manufacturing | $45.20/unit | Production costs for media. |
| Sales & Marketing (2022) | $19.4M | 18% of revenue. |
Revenue Streams
Biopreservation Media Sales
BioLife Solutions' revenue heavily relies on biopreservation media sales, like CryoStor and HypoThermosol, crucial for preserving cells and tissues. These products support manufacturing, storage, and distribution processes. This represents a recurring revenue stream, fueled by the expanding cell and gene therapy market. In 2024, sales from these preservation solutions reached $73.5 million.
Cell Processing Platform
BioLife Solutions' cell processing platform is a major revenue source. In Q4 2024, it hit a record $20.3 million, up 7% from Q3 and 37% year-over-year. For 2024, this platform generated $73.5 million, a 12% rise from 2023. This includes human platelet lysates (hPL) for cell expansion.
HypoThermosol and CryoStor Sales
BioLife Solutions primarily earns through biopreservation products, with 'CryoStor' being a key revenue driver. The company's revenue streams include sales of its proprietary HypoThermosol and CryoStor biopreservation media. In 2023, these specialized preservation solutions generated $71.3 million in revenue. This highlights the significance of these products in BioLife's financial performance. These revenues are crucial for the company's growth.
Services Revenue
BioLife Solutions boosts revenue through services like tech support, consulting, and training. These services help clients improve biopreservation and outcomes. Services revenue is expanding, fueled by the rising complexity of cell and gene therapy manufacturing. The company delivers biopreservation consulting, technical training, and customer success management to ensure optimal product usage.
- In 2023, BioLife's services revenue was a significant contributor to its total revenue, reflecting the growing demand for its expertise.
- This revenue stream is vital for supporting its product sales and fostering long-term customer relationships.
- BioLife's focus on customer success management ensures clients fully utilize and benefit from its products.
- The company's ability to provide specialized training and support is a key differentiator in the market.
Royalties and Licensing Fees
BioLife Solutions taps into revenue through royalties and licensing linked to its unique technologies. These fees arise when other businesses integrate BioLife's innovations into their offerings. This income stream is a high-margin source, boosting the company's financial health. As of December 31, 2024, their biopreservation media was in 17 approved cell and gene therapies.
- Royalties and licensing fees offer BioLife a profitable revenue stream.
- These fees come from other companies using BioLife's tech.
- The company anticipates 8 more approvals in the coming year.
- BioLife's biopreservation media supports approved therapies.
Revenue Streams: Media, Platform, and Services
BioLife Solutions has several revenue streams. These include sales of biopreservation media, such as CryoStor and HypoThermosol, which brought in $73.5 million in 2024. They also gain revenue from their cell processing platform, reaching $73.5 million in 2024. Additionally, BioLife earns from services and royalties.
| Revenue Stream | 2023 Revenue | 2024 Revenue |
|---|---|---|
| Biopreservation Media | $71.3M | $73.5M |
| Cell Processing Platform | N/A | $73.5M |
| Services | Significant | Expanding |
Business Model Canvas Data Sources
The BioLife Solutions Business Model Canvas integrates financial reports, market research, and strategic documents. This ensures accurate, reliable data for each section.
